Education
About Us
Working with TipRanks
Follow Us
Electrocore (ECOR)
:ECOR
ECOR Stock Chart & Stats
$5.05
$0.45(2.64%)
At close: 4:00 PM EST
$5.05
$0.45(2.64%)
Day’s Range― - ―
52-Week Range$4.16 - $19.49
Previous CloseN/A
Volume24.66K
Average Volume (3M)64.81K
Market Cap
$40.38M
Enterprise Value$39.41M
Total Cash (Recent Filing)$13.20M
Total Debt (Recent Filing)$10.81M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 05, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding7,995,903
10 Day Avg. Volume32,987
30 Day Avg. Volume64,805
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)16.08
Price to Sales (P/S)4.82
P/FCF Ratio-17.46
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$18.50Price Target Upside266.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$30.78M
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe VA/DoD prescribing facility count increased significantly, showing expansion in a key market channel.
Product PerformanceThe Quell product exceeded expectations, and its integration into the VA network is anticipated to significantly boost revenue.
Revenue GrowthElectrocore raised its 2025 revenue guidance, indicating strong performance and growth expectations.
Bears Say
Profitability ChallengesDelayed profitability is expected due to higher anticipated operating expenses, justifying a discounted valuation.
Electrocore News
ECOR FAQ
What was Electrocore’s price range in the past 12 months?
Electrocore lowest stock price was $4.16 and its highest was $19.49 in the past 12 months.
What is Electrocore’s market cap?
Electrocore’s market cap is $40.38M.
When is Electrocore’s upcoming earnings report date?
Electrocore’s upcoming earnings report date is Mar 05, 2026 which is in 93 days.
How were Electrocore’s earnings last quarter?
Electrocore released its earnings results on Nov 05, 2025. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.
Is Electrocore overvalued?
According to Wall Street analysts Electrocore’s price is currently Undervalued.
Does Electrocore pay dividends?
Electrocore does not currently pay dividends.
What is Electrocore’s EPS estimate?
Electrocore’s EPS estimate is -0.39.
How many shares outstanding does Electrocore have?
Electrocore has 7,995,903 shares outstanding.
What happened to Electrocore’s price movement after its last earnings report?
Electrocore reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went up 23.207%.
Which hedge fund is a major shareholder of Electrocore?
Currently, no hedge funds are holding shares in ECOR
Electrocore Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (266.34% Upside)
$18.50 (266.34% Upside)
Blogger Sentiment
Bullish
ECOR Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $13.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.77%
12-Months-Change
Fundamentals
Return on Equity
-337.84%
Trailing 12-Months
Asset Growth
1.74%
Trailing 12-Months
Company Description
Electrocore
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
ECOR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful strategic initiatives such as the NeuroMetrix acquisition and expansion in the VA system. However, these were balanced by increased net losses, delayed profitability, and ongoing legal challenges. Overall, the company is investing heavily in its future, which may pay off, but current financials are impacted.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$18.50
▲(266.34% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
20.82% Insiders
3.90% Mutual Funds
1.76% Other Institutional Investors
70.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---